SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549
                     ---------------------------------------

                                    FORM 8-K



                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934



 Date of Report (Date of earliest event reported): August 6, 2002 (August 2, 2002)
--------------------------------------------------------------------------------

                       INNOVATIVE CLINICAL SOLUTIONS, LTD.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                                    Delaware

--------------------------------------------------------------------------------
                 (State or other jurisdiction of incorporation)

               0-27568                              65-0617076
--------------------------------------------------------------------------------
          (Commission File Number) (IRS Employer Identification Number)

               10 Dorrance Street, Suite 400, Providence, RI 02903
--------------------------------------------------------------------------------
                    (Address of principal executive offices)

                                 (401) 831-6755
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

                                       N/A
--------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)






ITEM 4.   CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

The Securities and Exchange  Commission ("SEC") notified the Registrant that the
SEC had been notified by Arthur Andersen LLP ("AA"), the Registrant's auditor of
record,  that AA is unable to perform  future audit  services for the Registrant
and, as a result its relationship with the Registrant is effectively terminated.
The Registrant is currently in the process of identifying  qualified independent
auditors to replace AA and  anticipates  that it will have  retained a new audit
firm within 60 days.


During the two most recent fiscal years of the Registrant ended January 31, 2002
and 2001, and the subsequent  interim period through August 2, 2002,  there were
no  disagreements  between the  Registrant  and AA on any matters of  accounting
principles or practices,  financial statement  disclosure,  or auditing scope or
procedure, which disagreements, if not resolved to AA's satisfaction, would have
caused  AA to make  reference  to the  subject  matter  of the  disagreement  in
connection with its reports; and there were no reportable events described under
Item 304 (a) (1) (v) of Regulation S-K.



The  audit  reports  of AA on  the  consolidated  financial  statements  of  the
Registrant  as of and for the  fiscal  years  ended  January  31,  2002 and 2001
contained a going concern opinion explanatory  paragraph.  Except for such going
concern explanatory paragraph,  such reports did not contain any adverse opinion
or  disclaimers  of  opinion,   nor  were  they  qualified  or  modified  as  to
uncertainty,  audit scope or accounting principles. The Registrant has attempted
to obtain a letter from AA indicating  its  concurrence  with the  disclosure in
this and the  preceding  paragraph.  However,  AA has closed its Boston  office,
which had responsibility for the audit of the Registrant's  financial statements
and, accordingly, the Registrant is unable to provide such a letter from AA.



During the two most recent fiscal years of the Registrant ended January 31, 2002
and  2001  and the  subsequent  interim  period  through  August  2,  2002,  the
Registrant  did not  consult any other  accounting  firms  regarding  any of the
matters or events set forth in Item 304 (a) (2) (i) and (ii) of Regulation S-K.





ITEM 5. OTHER EVENTS

As previously  reported by the  Registrant,  on February 7, 2002, the Registrant
sold  its  wholly  owned  subsidiary,   Clinical  Studies,   Ltd.,   ("CSL")  to
Comprehensive  Neuroscience,  Inc. ("CNS") in exchange for CNS common stock. The
sale was  effected  through  the  merger  of CSL with a  subsidiary  of CNS (the
"Merger").



Subsequent to the Merger,  a dispute has arisen  between CNS and the  Registrant
involving CSL liabilities and post-closing adjustments to the CNS stock escrows.
The  Registrant has reached an agreement in principle for the settlement of this
dispute, which involves,  among other terms, a cash payment and an investment in
CNS by the Registrant, as well as modification of the escrow arrangement entered
into in  connection  with the  Merger to make  shares in the  Litigation  Escrow
available in satisfaction of any CSL working capital deficiency.  However, while
the  Registrant  and CNS have agreed upon the  principle  terms of a settlement,
such  settlement is conditioned  upon,  among other things,  the negotiation and
execution  of  definitive  documents  and  there  can be no  assurance  that any
settlement  with CNS will  ultimately be effected.  Failure of these  settlement
negotiations  could result in  litigation,  which could have a material  adverse
effect on the Registrant.


Forward Looking Statements


     Certain  statements  set  forth  above,  including,  but  not  limited  to,
statements containing the words "anticipates," "believes," "expects," "intends,"
"will," "may" and similar words constitute forward-looking statements within the
meaning  of  the  Private  Securities   Litigation  Reform  Act  of  1995.  Such
forward-looking  statements are based on management's  current  expectations and
include known and unknown risks,  uncertainties and other factors, many of which
the  results or  performance  to differ  materially  from any future  results or
performance  expressed  or implied  by such  forward-looking  statements.  These
statements involve risks,  uncertainties and other factors detailed from time to
time in the Registrant's  filings with the Securities and Exchange  Commissions.
The Registrant  cautions investors that any  forward-looking  statements made by
the  Registrant  are  not  guarantees  of  future  performance.  The  Registrant
disclaims any obligation to update any such factors or to announce  publicly the
results  of any  revisions  to any of the  forward-looking  statements  included
herein to reflect future events or developments.



ITEM 7. FINANCIAL STATEMENTS, PROFORMA FINANCIAL INFORMATION AND EXHIBITS.

(c) Exhibits.

         None







SIGNATURES

     Pursuant to the  requirements  of the  Securities  Exchange Act of 1934, as
amended,  the  Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.



INNOVATIVE CLINICAL SOLUTIONS, LTD.


By:  s/Gerald Hellerman
     -----------------------------
       Gerald Hellerman, Director


Date:  August 6, 2002